MedTrace Logo

Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C

NCT00322179 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2020-03-04

No results posted yet for this study

Summary

The response rate to interferon-based anti-viral therapy for chronic hepatitis C is lower in patients who are obese. However, it is not clear whether this is related to suboptimal dosing of the medication or alterated response in obese patients. Alterated immune response had been reported in obese patients. The goal of current study is to determine the immune response to interferon in obese compared to non-obese chronic hepatitis C in an tissue culture system.

Conditions

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Palo Alto Veterans Institute for Research

    lead OTHER

Principal Investigators

  • Ramsey Cheung, MD · VA Palo Alto Health Care System

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2007-11-30
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00322179 on ClinicalTrials.gov